Table 3.

Three-year cumulative incidence, incidence rate, hazard ratios, and subdistribution hazard ratios of receipt of a gout medication (allopurinol or colchicine) presented by level of kidney function and sex

eGFR, ml/min per 1.73 m23-Year Cumulative Incidence,a % (95% CI)Incidence Rate per 1000 Person-Years (95% CI)Hazard Ratio (95% CI)Subdistribution Hazard Ratio (95% CI)a
UnadjustedAdjustedbUnadjustedAdjustedb
Women
 ≥90 (n=21,498)0.3 (0.2 to 0.4)1.1 (0.9 to 1.4)1.0 (reference)1.0 (reference)1.0 (reference)1.0 (reference)
 60–89 (n=93,576)0.4 (0.4 to 0.5)1.6 (1.4 to 1.7)1.4 (1.1 to 1.9)1.6 (1.2 to 2.1)1.4 (1.1 to 1.8)1.7 (1.3 to 2.2)
 45–59 (n=29,780)0.9 (0.8 to 1.1)3.6 (3.2 to 4.0)3.3 (2.5 to 4.3)3.3 (2.5 to 4.4)3.2 (2.4 to 4.2)4.1 (3.0 to 5.5)
 30–44 (n=13,424)1.8 (1.6 to 2.0)7.5 (6.7 to 8.5)6.9 (5.3 to 9.0)6.7 (5.0 to 8.9)6.0 (4.6 to 7.9)7.7 (5.6 to 10.5)
 15–29 (n=3378)2.8 (2.2 to 3.4)13.4 (11.1 to 16.1)12.3 (9.1 to 16.6)11.1 (8.0 to 15.5)9.4 (6.8 to 12.9)11.6 (8.2 to 16.6)
 Dialysis (n=2104)1.2 (0.7 to 1.8)7.7 (5.5 to 10.5)13.8 (6.9 to 27.6)10.7 (5.2 to 22.1)3.9 (2.4 to 6.2)3.9 (2.3 to 6.6)
Men
 ≥90 (n=15,318)0.4 (0.3 to 0.5)1.6 (1.3 to 2.0)1.0 (reference)1.0 (reference)1.0 (reference)1.0 (reference)
 60–89 (n=74,539)0.7 (0.7 to 0.8)2.6 (2.4 to 2.8)1.6 (1.3 to 2.1)1.8 (1.4 to 2.3)1.8 (1.4 to 2.3)2.1 (1.6 to 2.7)
 45–59 (n=18,244)1.7 (1.6 to 1.9)6.7 (6.0 to 7.4)4.2 (3.2 to 5.4)4.1 (3.1 to 5.4)4.4 (3.3 to 5.8)5.6 (4.1 to 7.5)
 30–44 (n=6816)2.9 (2.6 to 3.3)12.9 (11.3 to 14.6)8.0 (6.2 to 10.5)7.5 (5.9 to 10.0)7.5 (5.6 to 10.0)9.4 (6.9 to 13.0)
 15–29 (n=1824)3.0 (2.3 to 3.8)15.6 (12.3 to 19.6)9.8 (7.0 to 13.6)8.4 (5.9 to 12.0)7.6 (5.3 to 10.9)9.2 (6.1 to 13.7)
 Dialysis (n=2424)2.3 (1.7 to 3.0)15.1 (12.1 to 18.8)10.4 (4.5 to 24.1)7.6 (3.2 to 18.1)5.7 (4.0 to 8.2)6.0 (3.9 to 9.2)
  • 95% CI, 95% confidence interval.

  • a Estimates derived from Fine and Gray method to account for the competing risk of death.

  • b Cox regression model looking at kidney function and gout, adjusted for age, diabetes, diuretic use, hypertension, and Charlson comorbidity index.